TOPICAL AVASTIN MAY DECREASE PKP GRAFT REJECTION

Eur J Ophthalmol 2009; 19: 870 - 872

Short-term topical bevacizumab (Avastin) therapy may potentially offer a safer and more effective alternative in treating graft rejection after penetrating keratoplasty (corneal transplant).

Comments

Popular posts from this blog

Keratoconus and Inflammatory Skin Conditions

CORNEA CROSS-LINKING RE-TREATMENT

IMPLANTABLE COLLAMER LENS APPEARS BETTER THAN LASIK OR PRK FOR MODERATE TO HIGH MYOPIC PATIENTS